MetaCap

Avalo Therapeutics (AVTX) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 57.1% versus a loss of 62.1%. Over five years, OVID leads with a -32.5% price change compared with -99.9% for AVTX. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $390.9 million), about 1.1 times the size.

Ovid Therapeutics converts more of its revenue into profit, with a net margin of -240.1% versus -132642.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTX-62.09%OVID+57.14%
+120%+24%-72%
Nov 21, 20251 yearNov 20, 2026
AVTX-99.89%OVID-36.05%
+21%-42%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTX versus OVID key metrics
MetricAVTXOVID
Share price$6.76$2.20
Market cap$390.88M$415.21M
1-day change+0.15%-5.98%
YTD return-62.78%+34.97%
1-year return-62.09%+57.14%
5-year return-99.89%-32.52%
EPS (TTM)$-2.26$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.00K$7.25M
Revenue growth (YoY)-86.62%+1181.27%
Net income (latest FY)$-78.26M$-17.41M
Operating margin-123601.69%-585.20%
Net margin-132642.37%-240.13%
52-week high$24.27$3.11
52-week low$6.53$1.26
Distance from 52-week high-72.15%-29.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+414.79%+179.55%
Average volume1.80M1.98M
Shares outstanding57.82M188.73M
Employees3323
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OVID has outperformed AVTX by 119.2 percentage points over the past year.
  • Ovid Therapeutics is more profitable, keeping -240.1 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
  • Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs -86.62%).

About Avalo Therapeutics

AVTX stock →

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

AVTX vs OVID FAQ

Which is bigger, Avalo Therapeutics or Ovid Therapeutics?

Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $390.88M for Avalo Therapeutics (AVTX).

Which stock has performed better over the past year, AVTX or OVID?

OVID returned +57.14% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.

Are Avalo Therapeutics and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons